Neuro-Oncology News

May is Brain Tumor Awareness Month.

A phase 1 trial showed chimeric antigen receptor T-cell therapy may hold promise for the treatment of glioblastoma.

The FDA granted accelerated approval to Ojemda for the treatment of certain children with relapsed or refractory low-grade glioma.

DENVER – For older adults with MS and signs of cancer, treatment with immune checkpoint inhibitors was safe and prevented relapse or disease progression, according to interim research.

The prolonged use of certain progestogen hormone drugs — such as medrogestone, medroxyprogesterone acetate and promegestone — increased the risk for developing intracranial meningioma, according to data published in The BMJ.

A novel bivalent-targeting, intrathecally delivered chimeric antigen receptor T-cell therapy decreased tumor size in patients with recurrent glioblastoma, according to results from a phase 1 study published in Nature Medicine.

Focused ultrasound could provide clinicians a safer alternative in diagnosing, monitoring and treating patients with brain tumors compared with biopsy, according to findings published in npj Precision Oncology.

A novel chimeric antigen receptor T-cell therapy produced significant tumor reductions in patients with glioblastoma, results from a phase 1 trial published in The New England Journal of Medicine showed.

WEST PALM BEACH, Fla. — Hispanic and Latino individuals with neuromyelitis optica spectrum disorder experienced improved outcomes with Uplizna compared with placebo, according to a poster from ACTRIMS 2024.

In this episode, host Shikha Jain, MD, speaks with Ashley Sumrall, MD, about advocacy outside of their oncology practices and organizations, what lies ahead for the field of neuro-oncology and more.